<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842516</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-12-1-02</org_study_id>
    <nct_id>NCT01842516</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study for LCB01-0371</brief_title>
  <official_title>A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, and Population Pharmacokinetics of LCB01-0371 in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary

        -  To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose

        -  To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral
           dose in healthy male subjects

        -  To investigate the safety of LCB01-0371 after a multiple oral dose in healthy male
           subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To investigate the PK characteristics of LCB01-0371 after a multiple oral dose

        -  To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of LCB01-0371</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of LCB01-0371</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 1200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg</intervention_name>
    <description>LCB0-0371 800mg</description>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <other_name>LCB0-0371 800mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 1200mg</intervention_name>
    <description>LCB01-0371 1200mg</description>
    <arm_group_label>LCB01-0371 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Health Male between 20 and 45 years of age at the time of screening and a subject with
             body mass index (BMI) between 19 and 27

          2. Medically healthy with no clinically significant screening results through Physical
             examination, x-ray, 12 lead ECG, Laboratory test

          3. Able to donate blood during study period and follow visit.

          4. Agree to continue to use a reliable method of birth control until 60 days after study
             completion.

          5. Capable of giving written informed consent and Able to understand and comply with
             protocol requirements, instructions and protocol-stated restrictions.

        Exclusion Criteria:

          1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic,
             neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).

          2. History of gastrointestinal problem which is affect to absorption within 6 months from
             screening

          3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the
             LCB01-0371, same class of the study drugs (linezolid), or other drugs including
             aspirin and antibiotics.

          4. History drug abuse or positive result of urine drug screening test for amphetamine,
             methamphetamine, barbiturate, cocaine, opiate, benzodiazepine, cannabinoid, methadone,
             etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

